Skip to main content
    C

    CorMedix Inc (CRMD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.67
    -0.15 (-3.11%)

    Market Cap: $370.64M

    Last updated: Nov 17, 2026 at 4:18 PM ET

    CorMedix Inc (CRMD) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    CorMedix (CRMD) has a market cap of $370.64M and an enterprise value of $160.92M. Revenue grew 87.70% over the last 12 months from the 12 months before. It holds $209.73M more cash than debt, 56.58% of its market cap.

    Total Valuation

    Enterprise value is 56.58% below the market cap, as cash exceeds debt.

    Market Cap$370.64M
    Enterprise Value$160.92M
    Latest price (Nov 17, 2026)$4.67

    Key Dates

    The next earnings report is expected on Mar 3, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 3, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.01% in the quarter ended Sep 30, 2026 and grew 15.48% a year over 2 years.

    Shares Outstanding78.45M
    Shares Change (YoY)+3.32%
    Shares Change (QoQ)+0.01%
    Share Count Growth (2Y CAGR)+15.48%

    Valuation Ratios

    Sales and book value multiples are 0.9x and 0.8x.

    P/E Ratio6.1x
    Forward P/E9.2x
    P/S Ratio0.9x
    Forward P/S1.1x
    P/B Ratio0.8x
    P/TBV Ratio4.4x
    P/FCF Ratio1.2x
    P/OCF Ratio1.2x

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 0.9x EBITDA and 0.5x free cash flow.

    EV / Earnings2.5x
    EV / Sales0.4x
    EV / EBITDA0.9x
    EV / FCF0.5x

    Price Statistics

    The stock is down 58.45% over 52 weeks and trades 33.66% below its 50-day average.

    Beta (1Y)1.34
    52-Week Change-58.45%
    1-Month Change-36.72%
    3-Month Change-45.19%
    6-Month Change-40.28%
    5-Year Change+17.18%
    10-Year Change-45.50%
    Total Return (1Y)-58.45%
    Total Return (3Y CAGR)+5.21%
    Total Return (5Y CAGR)-1.16%
    Return vs SPY (1Y)-65.21%
    Max Drawdown (1Y)-63.39%
    Max Drawdown (3Y)-71.86%
    Sharpe Ratio (1Y)-1.12
    Correlation with SPY (1Y)0.27
    50-Day Average$7.04
    200-Day Average$7.53
    52-Week Range$4.65 to $13.02
    RSI (14 Days)26.1
    Average Volume (20 Days)2.17M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 2.43x current liabilities, and total debt is 0.31x shareholder equity.

    Current Ratio2.43x
    Quick Ratio2.22x
    Debt / Equity0.31x
    Debt / EBITDA0.84x
    Debt / FCF0.47x
    Interest Coverage53.54x

    Returns and Efficiency

    Return on invested capital is 13.94% over the last 12 months, against a 5-year average of -17.35%.

    Return on Equity (ROE)13.84%
    Return on Assets (ROA)6.96%
    Return on Invested Capital (ROIC)13.94%
    ROE (5Y Average)-29.18%
    ROA (5Y Average)-28.12%
    ROIC (5Y Average)-17.35%
    Asset Turnover0.48x
    Inventory Turnover2.02x
    Receivables Turnover3.38x
    Cash Conversion Cycle243 days

    Taxes

    Income tax took 52.46% of pretax income over the last 12 months.

    Income Tax (TTM)$70.49M
    Effective Tax Rate52.46%

    Scores

    CRMD has an Altman Z-Score of 1.58, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score1.58
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $402.25M over the last 12 months.

    Revenue$402.25M
    Revenue Growth (YoY)+87.70%
    Gross Profit$319.56M
    Operating Income$159.08M
    Pretax Income$134.38M
    Net Income$63.89M
    EBITDA$173.08M
    Reported EPS (TTM)$0.76

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 50.31% of the $917.75M in total assets.

    Cash and Equivalents$355.15M
    Total Debt$145.42M
    Net Cash$209.73M
    Net Cash Per Share$2.67
    Working Capital$295.70M
    Shareholder Equity$461.71M
    Book Value Per Share$5.89
    Tangible Book Value$83.53M
    Tangible Book Per Share$1.06
    Total Assets$917.75M
    Total Liabilities$456.04M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $4.92M of capital spending, operating cash flow left $307.86M of free cash flow.

    Operating Cash Flow$312.78M
    Capital Expenditures$4.92M
    Free Cash Flow$307.86M
    FCF Per Share$3.87
    Depreciation and Amortization$42.88M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 39.55%.

    Gross Margin79.44%
    Operating Margin39.55%
    Pretax Margin33.41%
    Net Margin15.88%
    EBITDA Margin43.03%
    FCF Margin76.53%

    Growth

    Revenue grew 1557.48% a year over 3 years.

    Revenue Growth (3Y CAGR)+1557.48%
    Revenue Growth (5Y CAGR)+315.94%
    Book Value Per Share Growth (2Y CAGR)+87.91%

    Revenue and profit by year

    Dividends and Yields

    CRMD does not pay a dividend. Its free cash flow yield is 84.03%.

    Earnings Yield16.39%
    FCF Yield84.03%
    Buyback Yield3.21%
    Shareholder Yield3.21%

    Stock Splits

    The last split was a 1-for-5 reverse split on Mar 26, 2019.

    Last Split DateMar 26, 2019
    Split TypeReverse split
    Split Ratio1:5

    Peer Position

    Against 6 similar companies, CRMD has the lowest P/S.

    P/S Ratio0.9x vs 4.1x median
    ROIC13.94% vs -32.76% median
    Revenue Growth (Trailing 4 Quarters, YoY)+87.70% vs -55.23% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 2.38% and EPS growth at -72.44% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+2.38%
    EPS Growth Forecast (2Y CAGR)-72.44%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CRMD

    What is CRMD's market cap?

    CorMedix has a market cap of $370.64M. Its enterprise value, which adds debt and subtracts cash, is $160.92M.

    What is CRMD's P/E ratio?

    CorMedix has a trailing P/E ratio of 6.1x and a forward P/E of 9.2x.

    How many shares of CRMD are outstanding?

    CorMedix has 78.45M shares outstanding. The count is up 3.32% from a year earlier.

    Does CRMD pay a dividend?

    No. CorMedix does not pay a dividend.

    How much debt does CRMD have?

    CorMedix has $145.42M of total debt and $355.15M of cash and equivalents, a net cash position of $209.73M.